So what do we actually do about this? Because saying “keep it simple” is easy. Changing incentive structures is harder.
Well, if Dustin sees no problem in talking about it, and it's become a major policy concern, then I guess I should disclose that I spent a while talking with Dario back in late October 2022 (ie. pre-RSP in Sept 2023), and we discussed Anthropic's scaling policy at some length, and I too came away with the same impression everyone else seems to have: that Anthropic's AI-arms-race policy was to invest heavily in scaling, creating models at or pushing the frontier to do safety research on, but that they would only release access to second-best models & would not ratchet capabilities up, and it would wait for someone else to do so before catching up. So it would not contribute to races but not fall behind and become irrelevant/noncompetitive.[4]
，这一点在PDF资料中也有详细论述
Why the FT?See why over a million readers pay to read the Financial Times.
对此，北交所也要求乔路铭补充说明补充流动资金及融资规模测算依据是否充分、客观，是否存在资金闲置风险。(文 | 公司观察，作者 | 邓皓天，编辑 | 曹晟源)
Scientists have hailed a potentially life-changing drug for children with a hard to treat form of epilepsy, after promising early clinical trial results.